abstract:Desmoteplase is a novel, highly fibrin-specific thrombolytic agent in phase III of clinical development. In 2009, two large trials (DIAS-3 and DIAS-4) were started, and the results of these studies will determine whether desmoteplase will gain marketing authorization as a safe and effective treatment for patients with acute ischaemic stroke.
German biotech startup Paion has been shepherding through trials a genetically engineered version of a protein called desmoteplase, found in the saliva of vampire bats.